Abstract 44P
Background
Sitra is a spectrum-selective tyrosine kinase inhibitor targeting multiple receptors, including VEGFR2. Here, we present an exploratory analysis of PD biomarkers in SAFFRON-103, a phase 1b study investigating Sitra with TIS, an anti-PD-1 antibody, in patients (pts) with solid tumors including advanced non-squamous-non-small cell lung cancer (NSCLC), squamous-NSCLC, melanoma, or ovarian cancer.
Methods
Peripheral blood samples were collected at Cycle (C) 1 Day (D) 1, C2D1, and C3D1 prior to Sitra dosing, to investigate changes in cytokines (Meso Scale Discovery [MSD] multiplexing), plasma proteins (ELISA), and immune cell populations (fluorescence-activated cell sorting [FACS]). Generalized linear mixed models were used to estimate fold change and analyze biomarker changes; Wald tests were used to generate P-values.
Results
Baseline characteristics were balanced across pts with evaluable biomarker results (n=186 cytokines/plasma proteins, n=113 immune cell populations) and in the overall population (N=216). For all pts, changes in individual biomarker levels were consistent from C1D1 to both C2D1 and C3D1, with significant increases in VEGFA (P<0.0001; both) and CXCL10 (P<0.0001; both) and significant decreases across soluble (s) VEGFR2 (P<0.0001; both), peripheral G-MDSCs (P=0.0005; P=0.0002), and monocytes (P<0.0001; both). Estimated fold changes of PD biomarkers across tumor types are shown (Table). Changes in VEGFA (increased) and monocytes (decreased) after treatment (C2D1/C1D1) were associated with improved objective response rates (odds ratio [OR] 4.67, P=0.0005; OR 5.82, P<0.0001). Table: 44P
Estimated fold change from C1D1 | Non-squamous-NSCLC | Squamous-NSCLC | Melanoma | Ovarian cancer | ||||
C2D1 | C3D1 | C2D1 | C3D1 | C2D1 | C3D1 | C2D1 | C3D1 | |
ELISA/MSD eligible | n=60 | n=48 | n=22 | n=54 | ||||
VEFGA | 2.77 | 2.65 | 2.53 | 2.53 | 2.89 | 2.38 | 2.16 | 2.14 |
sVEFGR2 | 0.67 | 0.63 | 0.61 | 0.59 | 0.65 | 0.66 | 0.70 | 0.69 |
CXCL10 | 1.70 | 1.97 | 1.65 | 1.43 | 1.75 | 1.44 | 2.21 | 1.90 |
FACS eligible | n=44 | n=21 | n=10 | n=28 | ||||
G-MDSCs | 0.74 | 0.71 | 0.59 | 0.60 | 0.83 | 0.74 | 0.81 | 0.84 |
Monocytes | 0.70 | 0.72 | 0.72 | 0.64 | 0.73 | 0.72 | 0.81 | 0.85 |
Abbreviations: G-MDSC, granulocyte-like myeloid derived suppressor cells; NSCLC, non-small cell lung cancer; VEFGA, vascular endothelial growth factor A; sVERGR2, soluble vascular endothelial growth factor receptor 2
Conclusions
VEGFA increased and sVEGFR2 decreased consistently and significantly after Sitra plus TIS therapy, demonstrating the on-target anti-angiogenesis effect of Sitra. Decrease of G-MDSCs and monocytes in peripheral blood indicates a potential immune-modulating role for Sitra with TIS.
Clinical trial identification
NCT03666143.
Editorial acknowledgement
This study was sponsored by BeiGene, Ltd. Medical writing support, under the direction of the authors, was provided by Gemma Walker, BSc, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd.
Legal entity responsible for the study
BeiGene.
Funding
BeiGene.
Disclosure
Y. Wu: Non-Financial Interests, Personal, Advisory Role: AstraZeneca; Non-Financial Interests, Personal and Institutional, Coordinating PI: AstraZeneca, Roche, Merck; Financial Interests, Personal, Invited Speaker: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hengrui, MSD, Pfizer, Roche; Non-Financial Interests, Personal, Leadership Role: Chinese Thoracic Oncology Group (CTONG); Non-Financial Interests, Personal, Local PI: BeiGene, Innoven; Non-Financial Interests, Personal, Member: ASCO, ESMO, IASLC, CSCO; Financial Interests, Institutional, Research Grant: BMS, Pfizer. J.C. Goh: Non-Financial Interests, Institutional, Invited Speaker: Brisbane Cancer Conference; Financial Interests, Personal, Invited Speaker: GSK, MSD; Financial Interests, Personal, Speaker’s Bureau: MSD, GSK, Ipsen, Janssen, Eisai, AstraZeneca; Financial Interests, Personal, Advisory Board: Janssen, GSK, BMS, MSD, AstraZeneca; Financial Interests, Personal and Institutional, Full or part-time Employment, Part-time employment: Royal Brisbane & Women’s Hospital; Financial Interests, Personal and Institutional, Full or part-time Employment: ICON Chermside & Greenslopes; Financial Interests, Personal, Stocks/Shares: ICON Cancer Centres, Immutep; Non-Financial Interests, Personal and Institutional, Project Lead, Ceased; Collaborative Group: ITTACc trial; Non-Financial Interests, Institutional, Principal Investigator: MSD, BMS, Janssen, AstraZeneca, BeiGene, Sutro Biopharma, Exelixis, Pfizer, Alloplex, Alkermes, Mersana; Non-Financial Interests, Personal and Institutional, Member, Corporative trials group in ANZ, USA & Europe: ASCO, ANZGOG, ANZUP, ESMO; Non-Financial Interests, Institutional, Leadership Role: Member of ICON Cancer Centre MAC (Medical Advisory Committee). J. Zhao: Non-Financial Interests, Institutional, Coordinating PI: AstraZeneca; Non-Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, Merck, BeiGene, Pfizer; Non-Financial Interests, Personal, Local PI: Merck, Roche; Non-Financial Interests, Personal, Steering Committee Member: Pfizer, Pierre Fabre, BeiGene. Q. Zhou: Financial Interests, Personal, Speaker, Consultant, Advisor: Lecture and presentations fees to myself from AstraZeneca; Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, Sanofi outside the submitted work. M. Millward: Financial Interests, Personal, Advisory Board: BeiGene Australia Pty Ltd, Bristol Myers Squibb Australia Pty Ltd, AstraZeneca Australia Pty Ltd, The Limbic, Eli Lilly Australia Pty Ltd, IQVIA Australia Pty Ltd, Amgen Australia Pty Ltd, Merck Pte Ltd, Pfizer Australia Pty Ltd, Guardant Health, Roche Products Pty Ltd; Financial Interests, Personal, Full or part-time Employment, Employee: University of Western Australia; Financial Interests, Personal, Other, Consultant: Linear Clinical Research; Financial Interests, Institutional, Local PI, Trial payments to Institution: Bristol Myers Squibb, Genentech/Roche, BeiGene, Eli Lilly, Albion Laboratories, Akeso Biopharma, AbbVie, Five Prime Therapeutics, Dizal Pharma, Maxinovel, Amgen, Atridia, INXMED, Alpine Immune Sciences, Turning Point Therapeutics, IMPACT Therapeutics, Kinnate Biopharma, Rely Therapeutics, GenFleet Therapeutics, Vivace Therapeutics, Eucure Biopahrma, InventisBio, Cullinan Oncology, Tyra Biosciences, Axelia Oncology; Non-Financial Interests, Personal, Other, Scientific Advisory Committee member: Thoracic Oncology Group Australasia. T. Tian: Other, Institutional, Full or part-time Employment: GSDS, BeiGene USA, Inc. 1840 Gateway Drive, 3rd Floor, San Mateo, CA 94404; Financial Interests, Institutional, Stocks/Shares: GSDS, BeiGene USA, Inc. 1840 Gateway Drive, 3rd Floor, San Mateo, CA 94404. J. Guo: Financial Interests, Institutional, Speaker, Consultant, Advisor: Merck Sharp & Dohme, Roche, Bayer, Novartis, Simcere Pharmaceutical Group, Shanghai Junshi Biosciences, Oriengene. All other authors have declared no conflicts of interest.
Resources from the same session
137P - First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster Display
138P - Generation of frameshift mutated TGF_R2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF
Presenter: Else Inderberg
Session: Poster Display
139P - Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase 1 study
Presenter: Alexander Starodub
Session: Poster Display
140P - Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform
Presenter: Elli Sandberg
Session: Poster Display
141P - An IgE antibody targeting the melanoma-associated Chondroitin Sulfate Proteoglycan 4
Presenter: Lais Cristina Palhares
Session: Poster Display
142P - Identifying novel immunotherapy targets using machine learning and ex vivo validation
Presenter: Marcellus Augustine
Session: Poster Display
143P - Advancing Cancer Immunotherapy via HLA-G Pathway Modulation with UCB4594
Presenter: Ann WHITE
Session: Poster Display
144P - Discovery of CBO421, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer
Presenter: Simon Döhrmann
Session: Poster Display
145P - An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: ZONG SEAN JUO
Session: Poster Display
146P - A Novel Allosteric Oral Immunotherapy Small Molecule Modulates Adenosine 2A Receptor Signaling and Restores Anti-Tumor Immune Responses
Presenter: David Pejoski
Session: Poster Display